# ImmunityBio, Inc. (IBRX) Informational only - not investment advice. CIK: 0001326110 SIC: 2836 Biological Products, (No Diagnostic Substances) SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2836 Biological Products, (No Diagnostic Substances)](/industry/2836/) Latest 10-K filed: 2026-02-23 SEC page: https://www.sec.gov/edgar/browse/?CIK=1326110 Filing source: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm ## At a glance FY2025 · period end 2025-12-31 · filed 2026-02-23 · accession 0001326110-26-000030 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001326110.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 113,288,000 USD | 2025 | verified | | Net income | -351,398,000 USD | 2025 | verified | | Assets | 501,898,000 USD | 2025 | verified | | Free cash flow | -308,782,000 USD | 2025 | computed | | Revenue YoY | +668.31% | 2025 | computed | Stockholders' equity was not positive at FY2025 year-end (-500,469,000 USD, as filed); ROE and liabilities / equity are omitted rather than computed. Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). No market price, no rating, no forecast on this site. Not investment advice. ### Peer percentile fingerprint | Ratio | IBRX | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Revenue growth | 668.3% | 20.9% | 98 | 42 | | FCF margin | -272.6% | -127.6% | 43 | 43 | | ROA | -70.0% | -30.4% | 12 | 66 | | Current ratio | 5.10 | 5.52 | 46 | 66 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2836 Biological Products, (No Diagnostic Substances), not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 113288000 | USD | 2025 | 2026-02-23 | | Net income | -351398000 | USD | 2025 | 2026-02-23 | | Assets | 501898000 | USD | 2025 | 2026-02-23 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-23. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001326110.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | 44,000 | 45,000 | 47,000 | 2,202,000 | 605,000 | 934,000 | 240,000 | 622,000 | 14,745,000 | 113,288,000 | | Net income | -120,809,000 | -96,423,000 | -96,226,000 | -157,777,000 | -221,851,000 | -346,790,000 | -416,567,000 | -583,196,000 | -413,564,000 | -351,398,000 | | Operating income | -124,500,000 | -99,120,000 | -98,389,000 | -156,251,000 | -220,880,000 | -330,280,000 | -351,298,000 | -362,250,000 | -344,182,000 | -256,027,000 | | Diluted EPS | | | | -0.43 | -0.59 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 | | Operating cash flow | -38,593,000 | -48,780,000 | -63,381,000 | -152,109,000 | -171,724,000 | -274,419,000 | -337,509,000 | -366,757,000 | -391,236,000 | -304,936,000 | | Capital expenditures | 6,560,000 | 34,815,000 | 13,102,000 | 4,287,000 | 1,669,000 | 33,563,000 | 78,162,000 | 30,584,000 | 6,888,000 | 3,846,000 | | Assets | 317,496,000 | 250,440,000 | 181,950,000 | 143,123,000 | 221,381,000 | 468,910,000 | 362,356,000 | 504,452,000 | 382,933,000 | 501,898,000 | | Liabilities | 24,078,000 | 31,596,000 | 35,944,000 | 22,444,000 | 339,871,000 | 712,823,000 | 812,176,000 | 1,090,389,000 | 871,062,000 | 1,001,472,000 | | Stockholders' equity | 293,418,000 | 218,844,000 | 146,006,000 | 120,679,000 | -119,808,000 | -242,173,000 | -447,327,000 | -586,987,000 | -489,098,000 | -500,469,000 | | Cash and cash equivalents | 8,083,000 | 23,872,000 | 16,821,000 | 75,801,000 | 34,915,000 | 181,101,000 | 104,641,000 | 265,453,000 | 143,428,000 | 88,334,000 | | Free cash flow | -45,153,000 | -83,595,000 | -76,483,000 | -156,396,000 | -173,393,000 | -307,982,000 | -415,671,000 | -397,341,000 | -398,124,000 | -308,782,000 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Return on assets | -38.05% | -38.50% | -52.89% | -110.24% | -100.21% | -73.96% | -114.96% | -115.61% | -108.00% | -70.01% | | Current ratio | 16.34 | 6.35 | 3.26 | 4.82 | 1.64 | 0.91 | 0.28 | 5.05 | 3.36 | 5.10 | ## As-reported value updates 12 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/IBRX/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-04. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001326110.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2022-Q3 | 2022-09-30 | | | -0.28 | reported discrete quarter | | 2022-Q4 | 2022-12-31 | 73,000 | | | derived Q4 = FY annual - nine-month YTD | | 2023-Q1 | 2023-03-31 | 360,000 | | -0.27 | reported discrete quarter | | 2023-Q2 | 2023-06-30 | 41,000 | | -0.32 | reported discrete quarter | | 2023-Q3 | 2023-09-30 | 82,000 | -95,582,000 | -0.19 | reported discrete quarter | | 2023-Q4 | 2023-12-31 | 139,000 | -233,392,000 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2024-03-31 | 40,000 | -134,109,000 | -0.20 | reported discrete quarter | | 2024-Q2 | 2024-06-30 | | -134,564,000 | -0.20 | reported discrete quarter | | 2024-Q3 | 2024-09-30 | | -85,729,000 | -0.14 | reported discrete quarter | | 2024-Q4 | 2024-12-31 | | -59,162,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2025-03-31 | 16,517,000 | -129,646,000 | -0.15 | reported discrete quarter | | 2025-Q2 | 2025-06-30 | 26,425,000 | -92,555,000 | -0.10 | reported discrete quarter | | 2025-Q3 | 2025-09-30 | 32,061,000 | -67,253,000 | -0.07 | reported discrete quarter | | 2025-Q4 | 2025-12-31 | 38,285,000 | -61,944,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2026-03-31 | 44,206,000 | -632,782,000 | -0.62 | reported discrete quarter | | 2026-Q2 | 2026-06-30 | 51,240,000 | -230,378,000 | -0.22 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from IBRX's latest 10-K: [/company/IBRX/business/](/company/IBRX/business/). ## Risk Factors Verbatim Item 1A Risk Factors from IBRX's latest 10-K: [/company/IBRX/risk-factors/](/company/IBRX/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high Filing date: 2026-08-04 Report date: 2026-06-30 ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Forward-Looking Statements The following discussion and analysis of our financial condition and results of operations should be read together with the description of our business and the condensed consolidated financial statements and related notes thereto Part I, Item 1. “Financial Statements” in this Quarterly Report. This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on our management’s beliefs and assumptions and on information currently available to our management. Actual results could differ materially from those discussed in or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report, particularly in Part II, Item 1A. “Risk Factors.” Except as required by law, we do not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any document, whether as a result of new information, future events, or otherwise. Forward-looking statements include, but are not limited to: •our ability to successfully commercialize ANKTIVA globally in current and future approved indications (including NMIBC and NSCLC), and to obtain incremental regulatory approvals for new indications (including BCG-unresponsive NMIBC with CIS, with or without papillary tumors, BCG-unresponsive NMIBC papillary only, and NSCLC) from the FDA and applicable international regulatory agencies; •our expectations regarding the operation and effectiveness of our approved product and product candidates and related benefits, potential future uses and applications of our approved product and product candidates, including potential use in cancer vaccines and across multiple tumor types, and the benefits and uses or our strategy and technology generally; •our ability to obtain additional financing to fund our operations and advance the commercialization of our approved product and the development and commercialization of our other product candidates; •our ability to comply with the terms, conditions, covenants, restrictions, and obligations set forth in the RIPA and related transaction documents; •our ability to forecast operating results, including estimates regarding our future revenue and operating expenses, and make period-to-period comparisons predictive of future performance, including due to the impact of fluctuations in warrant, derivative, and fair value accounting measurement values; •our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry; •our beliefs regarding the success, cost and timing of our approved product and product candidate development activities and current and future clinical trials and studies, including study design, the enrollment of patients, and the timing of data readouts related thereto; •our expectations regarding our ability to utilize the Phase 1/2 aNK, haNK®, taNK, and NK-CAR (t-haNK™) clinical trials data to support the development of our product candidates, including our NK-CAR (t-haNK), MSC, and M-ceNK™ product candidates; the timing or likelihood of regulatory filings or other actions and related regulatory authority responses in the U.S. and jurisdictions outside of the U.S., including any planned meetings, investigational new drug, BLA, NDA or marketing authorization application or similar filings or pursuit of accelerated regulatory approval pathways or orphan drug status and Breakthrough Therapy, Fast Track or RMAT designations and any designation’s impact on BLA submission filing or approval timing and or approval probability; •the ability and willingness of various third parties to engage in research and development activities involving our product or product candidates, and our ability to leverage those activities; •our ability to enter into and successfully execute on clinical, regulatory and commercial arrangements internationally to accelerate the development and commercialization of ANKTIVA and our other product candidates; 38 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) •our expectations regarding the ease of administration and patient compatibility associated with our approved product and product candidates; •our beliefs regarding the potential markets for our approved product and product candidates and our ability to serve those markets, including the rate and degree of market acceptance of any approved products; •our beliefs regarding the potential manufacturing and distribution benefits associated with our approved product and product candidates, and our third-party CMOs’ abilities to follow cGMP standards to scale up the production of our approved product and product candidates; •our plans regarding manufacturing and distribution of our approved product and potential future products, including the enhancement of our in-house manufacturing capabilities; •our ability to attract and retain key personnel; •our ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for our approved product and our other product candidates, and other technologies in development; •the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product, product candidates and technology; •our expectations regarding the results of market access initiatives and coverage under medical reimbursement policies; •our expectations regarding the abilities of our international partners to drive commercialization of ANKTIVA in the EU and Middle East and North Africa regions; •the expected shelf life of ANKTIVA drug substance and drug product and availability of product supply; •our global expansion efforts and the accuracy of our assumptions related to tariffs and government policy changes, including Most-Favored Nation Prescription Drug Pricing; •any government shutdown or budget disruption, which could adversely affect the U.S. and global economies, and materially and adversely affect our business and/or our future BLA submissions; •the impact on us, if any, if the CVRs held by former Altor stockholders become due and payable; and •regulatory developments in the U.S. and foreign countries. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “would,” “strategy,” and variations of such words or similar expressions. and the negatives of those terms. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. These statements are based upon information available to us as of the date of this Quarterly Report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. 39 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part II, Item 1A. “Risk Factors” of this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Quarterly Report. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. ImmunityBio, ImmunityBio Care, ANKTIVA, ThAnktiva, haNK, taNK, ceNK, NK-92, Nant Cancer Vaccine, BioShield (and other BioShield-related trademarks), NANT 001, NANT XL, NANT 001 and Design, QUILT, Outsmart Your Disease, Smart Therapies for Difficult Diseases, NantKwest, VivaBioCell, and Infacell are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates. ANKTIVA is approved or authorized in five regulatory jurisdictions, expanding its global footprint to 34 countries, for use in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors. ANKTIVA has also received marketing authorization from the EDE and accelerated conditional approval from the SFDA in combination with checkpoint therapy for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. Other than as set forth in such specific approved label, our product candidates, including N-803, are investigational agents that are restricted by federal law to investigational use only, and safety and efficacy have not been established by any agency, including, without limitation, the FDA. This Quarterly Report contains references to our products and trademarks and products and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report, including logos, artwork, and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ products or trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us, by any other companies. In this Quarterly Report, the terms “ImmunityBio,” “the company,” “we,” “us,” and “our” refer to ImmunityBio, Inc. and its subsidiaries. 40 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) Our Business ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield platform, which is [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm Complete FY 2025 MD&A: /company/IBRX/mda/fy2025/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high Filing date: 2026-02-23 Report date: 2025-12-31 ITEM 7.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following discussion and analysis of our financial condition and results of operations should be read together with the description of our business that appears in Part I, Item 1. “Business” and the consolidated financial statements and related notes thereto in Part II, Item 8. “Financial Statements and Supplementary Data” of this Annual Report. This discussion contains forward-looking statements as a result of many factors, including those set forth under Part I, Item 1. “Business—Forward-Looking Statements” and Item 1A. “Risk Factors” and elsewhere in this Annual Report. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. Actual results could differ materially from those discussed in or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. “Risk Factors.” Except as required by law, we do not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any document, whether as a result of new information, future events, or otherwise. Our Business ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. ANKTIVA is our lead biologic product and a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. We are commercializing ANKTIVA for the treatment of BCG-unresponsive NMIBC CIS with or without papillary tumors. ANKTIVA has received FDA Breakthrough Therapy designation for use in BCG-unresponsive NMIBC CIS in adult patients with or without papillary tumors. ANKTIVA is now approved in the U.S., UK, and Saudi Arabia for BCG-unresponsive NMIBC CIS with or without papillary tumors. In February 2026, the European Commission granted conditional marketing authorization in the EU for ANKTIVA for the same indication. In addition, ANKTIVA is conditionally approved in Saudi Arabia, for use in combination with a CPI, for the treatment of adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. The approved labels highlight ANKTIVA’s ability to simultaneously activate NK cells, cytotoxic T cells, and memory T cells. ANKTIVA in combination with our CAR-NK therapy (PD-L1 t-haNK) has received RMAT designation from the FDA for use in combination with standard-of-care chemotherapy/radiotherapy for the reversal of lymphopenia and treatment of multiply relapsed locally advanced or metastatic pancreatic cancer. Separately, the FDA has authorized an EAP for ANKTIVA to treat lymphopenia in adult patients with refractory or relapsed solid tumors, regardless of tumor type, who have progressed following first-line standard-of-care treatment, including chemotherapy, radiation, or immunotherapy. The EAP includes patients with solid tumors who have failed first-line therapy and have a low ALC (ALC 1,000/μL). We are seeking to expand development of ANKTIVA in combination with current standard-of-care therapies across multiple solid and liquid tumor indications including: •BCG-naïve NMIBC; •BCG-unresponsive NMIBC with papillary tumors; •Second-line NSCLC; •First-line NSCLC; 137 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) •Glioblastoma; •Indolent non-Hodgkin lymphoma, including Waldenström macroglobulinemia; •Pancreatic cancer; •Prostate cancer; and •Ovarian cancer. In addition, ANKTIVA has been selected by the NCI for evaluation in a cancer prevention study in patients with Lynch syndrome, and we are evaluating the combination of ANKTIVA with other agents in colorectal cancer. The company is also supporting an ongoing EAP for rBCG to help address U.S. supply constraints. We are also establishing or conducting trials in multiple myeloma, HCC, and TNBC. Significant Developments The following is a summary of selected significant developments affecting our business that occurred since the filing of our Quarterly Report on Form 10-Q dated September 30, 2025 with the SEC on November 5, 2025: ANKTIVA Updates •2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year. •ANKTIVA Unit Growth: 750% unit sales volume increase in 2025 compared to 2024. •Global Approvals in Bladder Cancer: ANKTIVA in combination with BCG for the treatment of BCG-unresponsive NMIBC CIS with or without papillary tumors is now authorized across four major regulatory jurisdictions—the U.S., UK, EU, and Saudi Arabia—encompassing 33 countries in total. •First Approval for Lung Cancer: ANKTIVA in combination with CPIs has been conditionally approved by the SFDA for the treatment of metastatic NSCLC, with commercial launch planned within 60 days; label expansion plans underway across multiple tumor types and for the treatment of lymphopenia. •Long-Term Patent Protection: ANKTIVA combinations with CPIs are protected by multiple issued patents, including U.S. Patent Nos. 9,925,247 and 11,071,774, with patent terms extending beyond 2035. •Commercial Partnerships: Formed a distribution partnership with Accord Healthcare in the EU, with an 85-person sales force deployed across 30 countries, and established an Irish subsidiary in Dublin to support the European launch; partnering with BioPharma & Cigalah Healthcare to expand access to ANKTIVA in Saudi Arabia and, over time, in the MENA region; formed a Kingdom of Saudi Arabia subsidiary to support KSA launch. Clinical and Regulatory Updates •ANKTIVA as a Backbone to the Cancer BioShield Platform: Growing enrollment in ongoing and planned key clinical trials in BCG-naïve bladder cancer, NSCLC, glioblastoma, sepsis, non-Hodgkin lymphoma, and treatment of lymphopenia •BCG-Unresponsive NMIBC with Papillary Tumors: The company applied to the NCCN to seek expansion of the BCG-unresponsive NMIBC guidelines to include papillary-only disease in addition to CIS with or without papillary tumors, and the company is awaiting a decision on the matter expected in late Q1 or early Q2 2026. 138 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) Pipeline Summary [[GREPCENT_TABLE]] [["Product Candidate","Indication","Phase","Status"],["ANKTIVA + BCG","BCG-unresponsive NMIBC CIS","Approved","FDA, MHRA and SFDA approval; EU (EMA) conditional marketing authorization"],["ANKTIVA + CPI","Progressing, metastatic NSCLC","Approved/Phase 3","SFDA conditional approval"],["ANKTIVA + BCG","BCG-na\u00efve NMIBC","Phase 2B","85% enrolled"],["ANKTIVA + BCG","BCG-unresponsive papillary","sBLA","Resubmission plan"],["ANKTIVA + PD-L1 CAR-NK","Recurrent GBM","Phase 2/3","Registration trial"],["ANKTIVA + PD-L1 CAR-NK","Pancreatic cancer","Phase 2","RMAT designation"],["CD19 CAR-NK + rituximab","NHL","Phase 1","QUILT-106"],["ANKTIVA","Lymphopenia (solid tumors)","Expanded Access","FDA EAP authorized"],["rBCG (Serum Institute)","NMIBC","Expanded Access","FDA EAP authorized"],["M-ceNK","Solid tumors","Phase 1","Completed"],["Ad-HPV","HPV","Phase 2","Initiated and enrolling"]] [[/GREPCENT_TABLE]] Cancer BioShield Platform Components Addressing the Immune System As of December 31, 2025, our pipeline includes clinical-stage programs in the following indications: •Bladder Cancer: BCG-unresponsive NMIBC CIS with or without papillary tumors (approved), BCG-unresponsive papillary, BCG-naïve NMIBC •Lung Cancer: Progressing, metastatic NSCLC in combination with CPIs (accelerated conditional approval in Saudi Arabia) •Lymphopenia: Tumor-agnostic treatment of chemotherapy/radiation-induced lymphopenia (EAP authorized) •Pancreatic Cancer: Advanced/metastatic disease (RMAT designation) •Glioblastoma: Recurrent GBM (registration trial) •Non-Hodgkin Lymphoma: Waldenström macroglobulinemia and other CD19+/CD20+ lymphomas •Colorectal Cancer/Lynch Syndrome: Cancer prevention in high-risk patients (NCI-sponsored) •Prostate Cancer: High-risk prostate cancer •Ovarian Cancer: Platinum-resistant ovarian cancer •Infectious Diseases: HIV, Long COVID, universal nucleocapsid vaccine •Apheresis Platform: M-ceNK with cryopreservation and storage 139 Table of Contents ImmunityBio, Inc. and Subsidiaries Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued) Collaboration Agreements We anticipate that strategic collaborations will continue to be an integral part of our operations, providing opportunities to leverage our partners’ expertise and capabilities to gain access to new markets for our approved product and acquire new technologies or further expand the potential of our technologies, approved product and product candidates across relevant platforms. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically-integrated platforms and through complementary strategic partnerships. We believe that our innovative approach to orchestrate and combine therapies for optimal immune system response will become a therapeutic foundation across multiple indications. Additionally, we believe that data from multiple clinical trials indicates ANKTIVA has broad potential to enhance the activity of therapeutic mAbs, including CPIs, across a wide range of tumor types and potentially rescue lymphopenia by proliferation and activation of NK and T cells. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See Part I, Item 1. “Business—Collaboration and License Agreements” in this Annual Report for a more detailed discussion regarding our collaboration and license agreements. Agreements with Related Parties Our Executive Chairman and Global Chief Scientific and Medical Officer also founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Founder, Executive Chairman and Global Chief Scientific and Medical Officer. Related-Party Debt See Note 14 “Related-Party Debt” of the “Notes to Consolidated Financial Statements” that appears in Part II, Item 8. “Financial Statements and Supplementary Data” of this Annual Report for more information regarding our related-party debt. NantWorks, LLC Our Founder, Executive Chairman and Global Chief Scientific and Medical O [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2025 MD&A: /company/IBRX/mda/fy2025/ All MD&A years: /company/IBRX/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2024 MD&A](/company/IBRX/mda/fy2024/): filed 2025-03-03; accession 0001326110-25-000033 (https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm) - [FY 2023 MD&A](/company/IBRX/mda/fy2023/): filed 2024-03-19; accession 0001326110-24-000037 (https://www.sec.gov/Archives/edgar/data/1326110/000132611024000037/ibrx-20231231.htm) - FY 2022: filed 2023-03-01; accession 0001326110-23-000018 (https://www.sec.gov/Archives/edgar/data/1326110/000132611023000018/ibrx-20221231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year. - FY 2021: filed 2022-03-01; accession 0001326110-22-000011 (https://www.sec.gov/Archives/edgar/data/1326110/000132611022000011/ibrx-20211231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year. ## FDA-approved drug applications Applications listed under this company's exact-matched sponsor name. Approved applications only. No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule. Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers. This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent. ## Macro cross-references Indicators mapped to this company's SIC classification (industry 2836 Biological Products, (No Diagnostic Substances)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index - [TCU](/indicator/TCU/): Capacity Utilization: Total Index - [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity - [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/IBRX.md · JSON record: /company/IBRX.json · verified financials: /company/IBRX/financials.json / /company/IBRX/financials.csv · machine TOC for the whole site: /llms.txt